Search - tctmd.com

Displaying 1 - 5 of 5

Sort: Relevancy | Date

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

News Conference News VIVA 2022

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

November 03, 2022

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

News Conference News VIVA 2021

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

October 12, 2021

News Conference News VIVA 2016

Longer Term, IN.PACT SFA Trial and Global Registry Continue to Support DCB Therapy as an Option

October 12, 2016

News Conference News VIVA 2016

Long PAD Lesions Respond Well to DCB, but Optimal Patient Selection Still Unclear

September 21, 2016

Positive Results Continue at 2 Years for Paclitaxel-Eluting PAD Stent

News Conference News VIVA 2016

Positive Results Continue at 2 Years for Paclitaxel-Eluting PAD Stent

September 20, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.